Pyxis Oncology, Inc. PYXS 深 滬
等待開盤 11-06 09:30:00 美东时间
3.905
+0.005
+0.13%
華盛通- 最 高4.01
- 今 開3.93
- 成交量 61.71万股
- 最 低 3.84
- 昨 收 3.90
- 總市值 2.42亿
- 52周最高 4.31
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.8332
- 委 比 -22.93%
- 總股本 6201.81万
- 歷史最高 19.00
- 量 比 1.00
- 振 幅 4.36%
- 歷史最低 0.8332
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
11-05 10:35
Guggenheim Maintains Buy on Pyxis Oncology, Raises Price Target to $7
Guggenheim analyst Brad Canino maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $5 to $7.
11-04 23:37
Pyxis Oncology shares are trading higher. The company reported Q3 financial results.
Pyxis Oncology shares are trading higher. The company reported Q3 financial res...
11-04 00:50
Pyxis Oncology Q3 EPS $(0.35) Misses $(0.34) Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.04 percent. This is unchanged from the same period last year.
11-03 20:09
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Pyxis Oncology announced that it will present translational data for micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting the extracellular matrix, at ESMO 2025 and AACR-NCI-EORTC 2025. MICVO employs a unique three-pronged mechanism of action, including direct tumor cell killing, bystander effect, and immunogenic cell death, to combat solid tumors. Data highlight MICVO's effects on tumor microenvironment remod...
10-13 20:05
美股牛股 | SEALSQ飙升近40%，与TSS达成合作共同开发安全半导体解决方案；SERV大涨超28%
SEALSQ飙升近40%，与TSS达成合作共同开发安全半导体解决方案；SERV大涨超28%，将与外卖公司DoorDash合作，扩大在美国的业务范围>>
10-10 19:16
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
Pyxis Oncology has appointed Alex Kane as Senior Vice President of Investor Relations & Capital Markets, bringing 20 years of experience in life sciences and capital markets. Kane previously worked at Guggenheim Securities and has managed IPOs and investor relations for biotech companies. His expertise in investor communication and capital markets is expected to support Pyxis Oncology's clinical advancements and milestones.
10-09 11:30
Guggenheim Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $5
Guggenheim analyst Brad Canino initiates coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and announces Price Target of $5.
09-04 21:54
Pyxis Oncology to Participate in September Investor and Industry Conferences
Pyxis Oncology announced that President and CEO Lara S. Sullivan will attend the 2025 Cantor Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference in September, participating in fireside chats and investor meetings. She will also present at the 2nd Annual ADC and Novel Conjugates Summit in Boston. Live webcasts of the Cantor and H.C. Wainwright events will be available on Pyxis Oncology’s website. The company f...
08-21 11:30
Pyxis Oncology Q2 EPS $(0.30) Beats $(0.35) Estimate, Sales $2.82M
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.77 percent. This is a 3.45 percent decrease over losses of $(0.29) per share from the
08-15 04:36
